A Comprehensive Investigation of Molecular Features and Prognosis of Lung Adenocarcinoma with Micropapillary Component Yang Zhang, MD, Rui Wang, PhD,

Slides:

Advertisements

Similar presentations

Lung Adenocarcinoma with Ipsilateral Breast Metastasis: A Simple Coincidence? Hsu-Ching Huang, MD, Jen-Fan Hang, MD, Mei-Han Wu, MD, Teh-Ying Chou, MD,

Advertisements

Integrative Genomic Analysis Reveals a High Frequency of LKB1 Genetic Alteration in Chinese Lung Adenocarcinomas Rong Fang, PhD, Chao Zheng, PhD, Yihua.

Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma Kazuya Takamochi, MD, Shiaki Oh, MD,

High Discrepancy of Driver Mutations in Patients with NSCLC and Synchronous Multiple Lung Ground-Glass Nodules Chunyan Wu, MD, Chao Zhao, MD, Yang Yang,

Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung Hyo Sup Shim, MD, PhD, Mari- Kenudson, MD, Zongli Zheng,

Clinical and the Prognostic Characteristics of Lung Adenocarcinoma Patients with ROS1 Fusion in Comparison with Other Driver Mutations in East Asian Populations

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,

Perioperative versus Preoperative Chemotherapy with Surgery in Patients with Resectable Squamous Cell Carcinoma of Esophagus Yang Zhao, MD, ZhiJun Dai,

Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations

ALK FISH and IHC: You Cannot Have One without the Other

Impact of Solid Minor Histologic Subtype in Postsurgical Prognosis of Stage I Lung Adenocarcinoma Tianxiang Chen, MD, PhD, Jizhuang Luo, MD, Haiyong.

Negative Thyroid Transcription Factor 1 Expression Defines an Unfavorable Subgroup of Lung Adenocarcinomas Yiliang Zhang, MD, Rui Wang, MD, PhD, Yuan.

The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR- Mutant Non–Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors

Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer Xizhao Sui, MD, Wei Jiang, MD, Haiqing Chen, MD, Fan.

Clinicopathologic Analysis of ROS1-Rearranged Non–Small-Cell Lung Cancer and Proposal of a Diagnostic Algorithm Heounjeong Go, MD, PhD, Dong-Wan Kim,

Durable Response to Tyrosine Kinase Inhibitor Therapy in a Lung Cancer Patient Harboring Epidermal Growth Factor Receptor Tandem Kinase Domain Duplication

APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26

Use of Oncogenic Driver Mutations in Staging of Multiple Primary Lung Carcinomas: A Single-Center Experience Ramsey Asmar, MD, Joshua R. Sonett, MD,

Strong Programmed Death Ligand 1 Expression Predicts Poor Response and De Novo Resistance to EGFR Tyrosine Kinase Inhibitors Among NSCLC Patients With.

Electronic Updates for JTO Readers

Role of CT and PET Imaging in Predicting Tumor Recurrence and Survival in Patients with Lung Adenocarcinoma Ho Yun Lee, MD, PhD, So Won Lee, MD, Kyung.

Leptomeningeal Carcinomatosis in Non–Small-Cell Lung Cancer Patients: Impact on Survival and Correlated Prognostic Factors Su Jin Lee, MD, Jung-Il Lee,

Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung Hyo Sup Shim, MD, PhD, Mari- Kenudson, MD, Zongli Zheng,

Pattern of lymphatic spread in thoracic esophageal squamous cell carcinoma: A single- institution experience Bin Li, MD, Haiquan Chen, MD, Jiaqing Xiang,

Prognostic Factors in Completely Resected Node-Negative Lung Adenocarcinoma of 3 cm or Smaller Jung-Jyh Hung, MD, PhD, Yi-Chen Yeh, MD, Yu-Chung Wu,

Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD

Tumor histology predicts mediastinal nodal status and may be used to guide limited lymphadenectomy in patients with clinical stage I non–small cell lung.

Effusion Immunocytochemistry as an Alternative Approach for the Selection of First-Line Targeted Therapy in Advanced Lung Adenocarcinoma Tzu-Hsiu Tsai,

Lung Cancer and Prognosis in Taiwan: A Population-Based Cancer Registry Bing-Yen Wang, MD, Jing-Yang Huang, Ching-Yuan Cheng, MD, Ching-Hsiung Lin, MD,

Clinical Characteristics and Outcomes for Patients With Thymic Carcinoma: Evaluation of Masaoka Staging Anya M. Litvak, MD, Kaitlin Woo, MS, Sara Hayes,

Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion–Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations.

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations Chao-Hua.

Erik Jakobsen, Maria Iachina, Karen Ege Olsen, Anders Green

High Incidence of EGFR Mutations in Korean Men Smokers with No Intratumoral Heterogeneity of Lung Adenocarcinomas: Correlation with Histologic Subtypes,

Clinical Outcomes and Prognosis of Recurrent Thymoma Management

Lung Adenocarcinomas Manifesting as Radiological Part-Solid Nodules Define a Special Clinical Subtype Ting Ye, MD, PhD, Lin Deng, MD, Shengping Wang,

Lung adenocarcinoma: Are skip N2 metastases different from non-skip?

Yang Zhang, MD, Haiquan Chen, MD, PhD

Comprehensive Analysis of the Discordance of EGFR Mutation Status between Tumor Tissues and Matched Circulating Tumor DNA in Advanced Non–Small Cell Lung.

Coexistence of Tyrosine Kinase Inhibitor-Sensitizing and Resistant EGFR Mutations in an Untreated Lung Adenocarcinoma Patient and Response to Erlotinib

Role of CT and PET Imaging in Predicting Tumor Recurrence and Survival in Patients with Lung Adenocarcinoma Ho Yun Lee, MD, PhD, So Won Lee, MD, Kyung.

Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non–Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis Bin-Chi Liao,

Integrative Genomic Analysis Reveals a High Frequency of LKB1 Genetic Alteration in Chinese Lung Adenocarcinomas Rong Fang, PhD, Chao Zheng, PhD, Yihua.

Erratum Journal of Thoracic Oncology

Lung Adenocarcinomas with HER2-Activating Mutations Are Associated with Distinct Clinical Features and HER2/EGFR Copy Number Gains Chenguang Li, MD,

Tumor Spread through Air Spaces Affects the Recurrence and Overall Survival in Patients with Lung Adenocarcinoma >2 to 3 cm Chenyang Dai, MD, Huikang.

Combination Treatment Using an EGFR Tyrosine Kinase Inhibitor plus Platinum-Based Chemotherapy for a Patient with Transformed Small Cell Carcinoma and.

Mitotic Inhibitors Journal of Thoracic Oncology

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

MET Expression Plays Differing Roles in Non–Small-Cell Lung Cancer Patients with or without EGFR Mutation Ling Huang, MS, She-Juan An, PhD, Zhi-Hong.

Mirror Mirror on the Wall, Who Is the Fairest of Them All

EGFR delE709_T710insD: A Rare but Potentially EGFR Inhibitor Responsive Mutation in Non–Small-Cell Lung Cancer Allison Ackerman, MD, Michael A. Goldstein,

Clinical and the Prognostic Characteristics of Lung Adenocarcinoma Patients with ROS1 Fusion in Comparison with Other Driver Mutations in East Asian Populations

EGFR Mutation and Brain Metastasis in Pulmonary Adenocarcinomas

Monotherapy Administration of Sorafenib in Patients With Non–Small Cell Lung Cancer (MISSION) Trial Luis Paz-Ares, MD, Vera Hirsh, MD, Li Zhang, MD,

Role of Postoperative Radiotherapy in Nonlocalized Thymoma

Spectrum of LKB1, EGFR, and KRAS Mutations in Chinese Lung Adenocarcinomas Bin Gao, BS, Yihua Sun, MD, Junhua Zhang, MD, Yan Ren, PhD, Rong Fang, BS,

Chemotherapy Response in East Asian Non-small Cell Lung Cancer Patients Harboring Wild-Type or Activating Mutation of Epidermal Growth Factor Receptors

Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR-Mutated Non– Small Cell Lung Cancer Emily Castellanos, MD, Emily Feld, MD, Leora.

Jie Huang, Juan Peng, Linlang Guo, MD, PhD

Impressive Response to Tyrosine Kinase Inhibitors in a Patient with Respiratory Failure for EGFR-Mutated Metastatic Lung Cancer Elena Bolzacchini, MD,

Outcome of Multimodality Treatment for 188 Cases of Type B3 Thymoma

Heterogeneity of EGFR Aberrations and Correlation with Histological Structures: Analyses of Therapy-Naive Isogenic Lung Cancer Lesions with EGFR Mutation

P Combined Molecular and Radiological Evaluation Unveils Three Subtypes of Disease Progression to a Third Generation EGFR TKI Y. Zhang, Q. Zhou,

The Clinical Impact of Solid and Micropapillary Patterns in Resected Lung Adenocarcinoma Naoki Yanagawa, MD, PhD, Satoshi Shiono, MD, PhD, Masami Abiko,

Bcl-2-Like Protein 11 Deletion Polymorphism Predicts Survival in Advanced Non–Small- Cell Lung Cancer Jih-Hsiang Lee, MD, Yu-Lin Lin, MD, Wei-Hsun Hsu,

APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28

Biomarkers in Early-Stage Non–Small-Cell Lung Cancer: Current Concepts and Future Directions Mauricio Burotto, MD, Anish Thomas, MD, Deepa Subramaniam,

Presentation transcript:

A Comprehensive Investigation of Molecular Features and Prognosis of Lung Adenocarcinoma with Micropapillary Component Yang Zhang, MD, Rui Wang, PhD, Deng Cai, MD, Yuan Li, MD, Yunjian Pan, MD, Haichuan Hu, MD, Lei Wang, MD, Hang Li, MD, Ting Ye, MD, Xiaoyang Luo, MD, Yiliang Zhang, MD, Bin Li, MD, Lei Shen, MD, Yihua Sun, MD, Haiquan Chen, MD Journal of Thoracic Oncology Volume 9, Issue 12, Pages 1772-1778 (December 2014) DOI: 10.1097/JTO.0000000000000341 Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Representative images of micropapillary predominant lung adenocarcinoma (A) and nonmicropapillary predominant (acinar predominant) adenocarcinoma with a micropapillary component of greater than or equal to 5% (B). Journal of Thoracic Oncology 2014 9, 1772-1778DOI: (10.1097/JTO.0000000000000341) Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Spectrum of oncogenic driver mutations in micropapillary predominant lung adenocarcinoma (MPP) and nonmicropapillary predominant adenocarcinoma with a micropapillary component of greater than or equal to 5% (MPC). Journal of Thoracic Oncology 2014 9, 1772-1778DOI: (10.1097/JTO.0000000000000341) Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 Recurrence-free survival and overall survival of micropapillary predominant lung adenocarcinoma (MPP), nonmicropapillary histologic subtype with a micropapillary component of greater than or equal to 5% (MPC) and MPC-negative adenocarcinoma in patients of all stages (A and B), stage I (C and D), and stages II–III (E and F). “MPC-” represents MPC-negative. “MPC+” represents MPC-positive, including MPP and MPC. Journal of Thoracic Oncology 2014 9, 1772-1778DOI: (10.1097/JTO.0000000000000341) Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 4 Postrecurrence survival of patients with EGFR-mutated lung adenocarcinoma harboring a micropapillary component of greater than or equal to 5% according to the administration of EGFR tyrosine kinase inhibitors (TKI). Journal of Thoracic Oncology 2014 9, 1772-1778DOI: (10.1097/JTO.0000000000000341) Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions